日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Unpacking bedaquiline heteroresistance: the importance of intermediate profiles for phenotypic drug susceptibility testing

解析贝达喹啉异质性耐药:中间谱对表型药物敏感性测试的重要性

Ismail, Nabila; Sirgel, Frik; Omar, Shaheed Vally; Omar, Shatha; de Kock, Marianna; Spies, Claudia; Folkerts, Megan; Theron, Grant; Engelthaler, Dave; Metcalfe, John; Warren, Robin M

Bedaquiline resistance in patients with drug-resistant tuberculosis in Cape Town, South Africa: a retrospective longitudinal cohort study

南非开普敦耐药结核病患者贝达喹啉耐药性:一项回顾性纵向队列研究

Derendinger, Brigitta; Dippenaar, Anzaan; de Vos, Margaretha; Huo, Stella; Alberts, Rencia; Tadokera, Rebecca; Limberis, Jason; Sirgel, Frik; Dolby, Tania; Spies, Claudia; Reuter, Anja; Folkerts, Megan; Allender, Christopher; Lemmer, Darrin; Van Rie, Annelies; Gagneux, Sebastien; Rigouts, Leen; Te Riele, Julian; Dheda, Keertan; Engelthaler, David M; Warren, Robin; Metcalfe, John; Cox, Helen; Theron, Grant

Enhanced Fatigue Limit in Ultrafine-Grained Ferritic-Martensitic Steel

超细晶粒铁素体-马氏体钢的疲劳极限增强

Nikitina, Marina A; Islamgaliev, Rinat K; Ganeev, Artur V; Frik, Aleksandra A

National lung cancer screening program feasibility study in Estonia

爱沙尼亚国家肺癌筛查项目可行性研究

Kallavus, Kadi; Laisaar, Kaja-Triin; Rätsep, Anneli; Kiudma, Tarvo; Takker, Urmas; Poola, Anneli; Makke, Vahur; Frik, Marianna; Viiklepp, Piret; Taur, Merily; Laisaar, Tanel

On-Field Tests for Patients After Anterior Cruciate Ligament Reconstruction: A Scoping Review

前交叉韧带重建术后患者的现场测试:一项范围界定综述

Welling, Wouter; Frik, Laurens

Cross-talk between monocyte invasion and astrocyte proliferation regulates scarring in brain injury

单核细胞侵袭和星形胶质细胞增殖之间的相互作用调节脑损伤中的瘢痕形成

Jesica Frik, Juliane Merl-Pham, Nikolaus Plesnila, Nicola Mattugini, Jacob Kjell, Jonas Kraska, Ricardo M Gómez, Stefanie M Hauck, Swetlana Sirko, Magdalena Götz

Development of a Novel Lead that Targets M. tuberculosis Polyketide Synthase 13

开发一种靶向结核分枝杆菌聚酮合酶13的新型先导化合物

Anup Aggarwal ,Maloy K Parai ,Nishant Shetty ,Deeann Wallis ,Lisa Woolhiser ,Courtney Hastings ,Noton K Dutta ,Stacy Galaviz ,Ramesh C Dhakal ,Rupesh Shrestha ,Shoko Wakabayashi ,Chris Walpole ,David Matthews ,David Floyd ,Paul Scullion ,Jennifer Riley ,Ola Epemolu ,Suzanne Norval ,Thomas Snavely ,Gregory T Robertson ,Eric J Rubin ,Thomas R Ioerger ,Frik A Sirgel ,Ruben van der Merwe ,Paul D van Helden ,Peter Keller ,Erik C Böttger ,Petros C Karakousis ,Anne J Lenaerts ,James C Sacchettini

Cyclometalated Iminophosphorane Gold(III) and Platinum(II) Complexes. A Highly Permeable Cationic Platinum(II) Compound with Promising Anticancer Properties

环金属化亚氨基膦金(III)和铂(II)配合物。具有良好抗癌特性的高渗透性阳离子铂(II)化合物

Malgorzata Frik, Jacob Fernández-Gallardo, Oscar Gonzalo, Víctor Mangas-Sanjuan, Marta González-Alvarez, Alfonso Serrano del Valle, Chunhua Hu, Isabel González-Alvarez, Marival Bermejo, Isabel Marzo, María Contel

Mycobacterium tuberculosis pncA Polymorphisms That Do Not Confer Pyrazinamide Resistance at a Breakpoint Concentration of 100 Micrograms per Milliliter in MGIT

在MGIT培养基中,当吡嗪酰胺的临界浓度为100微克/毫升时,结核分枝杆菌pncA多态性不赋予其耐药性。

Whitfield, Michael G; Warren, Robin M; Streicher, Elizabeth M; Sampson, Samantha L; Sirgel, Frik A; van Helden, Paul D; Mercante, Alexandra; Willby, Melisa; Hughes, Kelsey; Birkness, Kris; Morlock, Glenn; van Rie, Annelies; Posey, James E

In vitro and in vivo evaluation of water-soluble iminophosphorane ruthenium(II) compounds. A potential chemotherapeutic agent for triple negative breast cancer

水溶性亚氨基膦钌(II)化合物的体外和体内评价。三阴性乳腺癌的潜在化疗药物

Malgorzata Frik, Alberto Martínez, Benelita T Elie, Oscar Gonzalo, Daniel Ramírez de Mingo, Mercedes Sanaú, Roberto Sánchez-Delgado, Tanmoy Sadhukha, Swayam Prabha, Joe W Ramos, Isabel Marzo, María Contel